155 related articles for article (PubMed ID: 12181422)
1. A77 1726 induces differentiation of human myeloid leukemia K562 cells by depletion of intracellular CTP pools.
Huang M; Wang Y; Collins M; Mitchell BS; Graves LM
Mol Pharmacol; 2002 Sep; 62(3):463-72. PubMed ID: 12181422
[TBL] [Abstract][Full Text] [Related]
2. CPEC induces erythroid differentiation of human myeloid leukemia K562 cells through CTP depletion and p38 MAP kinase.
Huang M; Wang Y; Collins M; Graves LM
Leukemia; 2004 Nov; 18(11):1857-63. PubMed ID: 15385935
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of the antiproliferative action of leflunomide. A77 1726, the active metabolite of leflunomide, does not block T-cell receptor-mediated signal transduction but its antiproliferative effects are antagonized by pyrimidine nucleosides.
Cao WW; Kao PN; Chao AC; Gardner P; Ng J; Morris RE
J Heart Lung Transplant; 1995; 14(6 Pt 1):1016-30. PubMed ID: 8719445
[TBL] [Abstract][Full Text] [Related]
4. Cell cycle-dependent regulation of pyrimidine biosynthesis.
Sigoillot FD; Berkowski JA; Sigoillot SM; Kotsis DH; Guy HI
J Biol Chem; 2003 Jan; 278(5):3403-9. PubMed ID: 12438317
[TBL] [Abstract][Full Text] [Related]
5. The active metabolite of leflunomide, A77 1726, interferes with dendritic cell function.
Kirsch BM; Zeyda M; Stuhlmeier K; Grisar J; Smolen JS; Watschinger B; Stulnig TM; Hörl WH; Zlabinger GJ; Säemann MD
Arthritis Res Ther; 2005; 7(3):R694-703. PubMed ID: 15899055
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of p70 S6 kinase (S6K1) activity by A77 1726 and its effect on cell proliferation and cell cycle progress.
Doscas ME; Williamson AJ; Usha L; Bogachkov Y; Rao GS; Xiao F; Wang Y; Ruby C; Kaufman H; Zhou J; Williams JW; Li Y; Xu X
Neoplasia; 2014 Oct; 16(10):824-34. PubMed ID: 25379019
[TBL] [Abstract][Full Text] [Related]
7. The active metabolite of leflunomide, A77 1726, inhibits the production of prostaglandin E(2), matrix metalloproteinase 1 and interleukin 6 in human fibroblast-like synoviocytes.
Burger D; Begué-Pastor N; Benavent S; Gruaz L; Kaufmann MT; Chicheportiche R; Dayer JM
Rheumatology (Oxford); 2003 Jan; 42(1):89-96. PubMed ID: 12509619
[TBL] [Abstract][Full Text] [Related]
8. Identification of the binding site for the allosteric inactivator UTP in mammalian CPS II.
Zhu LM; Carrey EA
Biochem Soc Trans; 1995 Nov; 23(4):620S. PubMed ID: 8654805
[No Abstract] [Full Text] [Related]
9. Differential modulation of pro- and anti-inflammatory cytokine receptors by N-(4-trifluoromethylphenyl)-2-cyano-3-hydroxy-crotonic acid amide (A77 1726), the physiologically active metabolite of the novel immunomodulator leflunomide.
Mirmohammadsadegh A; Homey B; Abts HF; Köhrer K; Ruzicka T; Michel G
Biochem Pharmacol; 1998 May; 55(9):1523-9. PubMed ID: 10076546
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide.
Greene S; Watanabe K; Braatz-Trulson J; Lou L
Biochem Pharmacol; 1995 Sep; 50(6):861-7. PubMed ID: 7575649
[TBL] [Abstract][Full Text] [Related]
11. The active metabolite of leflunomide, A77 1726, increases proliferation of human synovial fibroblasts in presence of IL-1beta and TNF-alpha.
Magne D; Mézin F; Palmer G; Guerne PA
Inflamm Res; 2006 Nov; 55(11):469-75. PubMed ID: 17122964
[TBL] [Abstract][Full Text] [Related]
12. Characterization of pyrimidine metabolism in the cellular slime mold, Dictyostelium discoideum.
Wales ME; Mann-Dean MG; Wild JR
Can J Microbiol; 1989 Apr; 35(4):432-8. PubMed ID: 2568162
[TBL] [Abstract][Full Text] [Related]
13. CAD overexpression in mammalian cells.
Qiu Y; Davidson JN
Adv Exp Med Biol; 1998; 431():481-5. PubMed ID: 9598115
[No Abstract] [Full Text] [Related]
14. Regulation of carbamoyl phosphate synthetase by MAP kinase.
Graves LM; Guy HI; Kozlowski P; Huang M; Lazarowski E; Pope RM; Collins MA; Dahlstrand EN; Earp HS; Evans DR
Nature; 2000 Jan; 403(6767):328-32. PubMed ID: 10659854
[TBL] [Abstract][Full Text] [Related]
15. Effect of polyamines on the carbamoyl-phosphate synthase activity of CAD protein.
Szondy Z; Matyasi G; Elödi P
Acta Biochim Biophys Hung; 1989; 24(1-2):107-17. PubMed ID: 2481915
[TBL] [Abstract][Full Text] [Related]
16. Estrogens interfere with leflunomide modulation of cytokine production by human activated monocytes.
Montagna P; Soldano S; Brizzolara R; Villaggio B; Triolo P; Clerico P; Meroni M; Sulli A; Seriolo B; Molfetta L; Cutolo M
Ann N Y Acad Sci; 2010 Apr; 1193():30-5. PubMed ID: 20398005
[TBL] [Abstract][Full Text] [Related]
17. Uridylate-trapping sugar analogs in combination with inhibitors of uridylate synthesis de novo and 5-fluorouridine.
Keppler D; Fauler J; Gasser T; Holstege A; Leube K; Schulz-Holstege C; Weckbecker G
Adv Enzyme Regul; 1985; 23():61-79. PubMed ID: 2416194
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of HIV replication by A77 1726, the active metabolite of leflunomide, in combination with pyrimidine nucleoside reverse transcriptase inhibitors.
Hossain MM; Margolis DM
J Acquir Immune Defic Syndr; 2001 Oct; 28(2):199-201. PubMed ID: 11588518
[No Abstract] [Full Text] [Related]
19. Characterization of temperature-sensitive cytidine triphosphate synthase mutations in bacteria by high-performance liquid chromatography.
Bailey AJ; Dutta PK; Shanley MS; O'Donovan GA
J Chromatogr; 1990 Jul; 512():403-7. PubMed ID: 2229235
[TBL] [Abstract][Full Text] [Related]
20. The active metabolite of leflunomide, A77 1726, increases the production of IL-1 receptor antagonist in human synovial fibroblasts and articular chondrocytes.
Palmer G; Burger D; Mezin F; Magne D; Gabay C; Dayer JM; Guerne PA
Arthritis Res Ther; 2004; 6(3):R181-9. PubMed ID: 15142263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
